BioCentury
ARTICLE | Company News

Loxo completes larotrectinib NDA

March 26, 2018 8:38 PM UTC

Loxo Oncology Inc. (NASDAQ:LOXO) completed submission of a rolling NDA to FDA for larotrectinib (LOXO-101) to treat locally advanced or metastatic solid tumors with neurotrophic tyrosine kinase receptor (Trk) fusion-proteins, regardless of tissue of origin.

Larotrectinib is a small molecule inhibitor of neurotrophic tyrosine kinase receptor 1 (TrkA; NTRK1), TrkB (NTRK2) and TrkC (NTRK3). It has breakthrough therapy, Orphan Drug and rare pediatric disease designations from FDA...